Press Releases

 
Press Releases
  Date Title View
Sep 4, 2016
BERKELEY, CA -- (Marketwired) -- 09/04/16 -- Dynavax Technologies Corporation (NASDAQ: DVAX) announced today that the U.S. Food and Drug Administration's (FDA) Center for Biologics Evaluation and Research has cancelled the scheduled November 16, 2016, Vaccines and Related Biological Products Advisory Committee (VRBPAC) meeting to review the Biolog...
Aug 5, 2016
BERKELEY, CA -- (Marketwired) -- 08/05/16 -- Dynavax Technologies Corporation (NASDAQ: DVAX) today reported financial results for the second quarter and six months ended June 30, 2016. The Company had $139.0 million in cash, cash equivalents and marketable securities as of June 30, 2016, compared to $196.1 million at December 31, 2015. Th...
Aug 5, 2016
BERKELEY, CA -- (Marketwired) -- 08/05/16 -- Dynavax Technologies Corporation (NASDAQ: DVAX) announced today that the Vaccines and Related Biological Products Advisory Committee (VBRPAC) will review the Biologics License Application (BLA) for HEPLISAV-B™ [Hepatitis B Vaccine, Recombinant (Adjuvanted)] at its meeting on November 16, 2016. The...
Jun 11, 2016
BERKELEY, CA -- (Marketwired) -- 06/11/16 -- Dynavax Technologies Corporation (NASDAQ: DVAX) today announced preliminary results from a pivotal Phase 3 trial demonstrating that HEPLISAV-B [Hepatitis B Vaccine, Recombinant (Adjuvanted)] provided a significantly higher rate of seroprotection than Engerix-B®, an approved hepatitis B vaccine, in a...
May 18, 2016
BERKELEY, CA -- (Marketwired) -- 05/18/16 -- Dynavax Technologies Corporation (NASDAQ: DVAX) today announced that it will present at two upcoming investor conferences. Information relating to the two presentations follows: 2016 UBS Global Healthcare Conference Michael Ostrach, Dynavax's senior vice pre...
May 9, 2016
BERKELEY, CA -- (Marketwired) -- 05/09/16 -- Dynavax Technologies Corporation (NASDAQ: DVAX) today reported financial results for the first quarter ended March 31, 2016. The Company had $166.8 million in cash, cash equivalents and marketable securities as of March 31, 2016, compared to $196.1 million at December 31, 2015. The net lo...
Apr 27, 2016
BERKELEY, CA -- (Marketwired) -- 04/27/16 -- Dynavax Technologies Corporation (NASDAQ: DVAX) today announced that the U.S. Food and Drug Administration (FDA) will require additional time to complete its review of the Biologics License Application (BLA) for HEPLISAV-B™, Dynavax's investigational vaccine for immunization of adults agains...
Apr 18, 2016
BERKELEY, CA -- (Marketwired) -- 04/18/16 -- Dynavax Technologies Corporation (NASDAQ: DVAX) today announced encouraging additional data from Part 1 of a Phase 1/2 study (LYM-01) evaluating the company's lead immunotherapy product candidate, SD-101, in combination with low-dose radiation in lymphoma patients. The data were presented at the A...
Apr 18, 2016
BERKELEY, CA -- (Marketwired) -- 04/18/16 -- Dynavax Technologies Corporation (NASDAQ: DVAX) today announced results from HBV-23, a pivotal Phase 3 trial that provides head-to-head safety and immunogenicity data comparing its investigational adult hepatitis B vaccine, HEPLISAV-B, with the leading vaccine, Engerix-B, in adults 18 to 70 years ...
Apr 4, 2016
BERKELEY, CA -- (Marketwired) -- 04/04/16 -- Dynavax Technologies Corporation (NASDAQ: DVAX) today announced that it will present HEPLISAV-B pivotal Phase 3 data at the National Foundation for Infectious Diseases' 19th Annual Conference on Vaccine Research (ACVR). The Conference will take place in Baltimore, Maryland from April 18th throu...
FirstPrevious
3
...
NextLast
= add release to Briefcase